Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1/2 5Phase 1 4Phase 3 3Phase NA 1Phase 4 1

Status

Active not recruiting 11Completed 10Recruiting 8Unknown 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1HER2+ Breast Cancer 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Unknown × palbociclib × Clear all
NCT03423199 2024-03-22

PATHWAY

National Cancer Center, Japan

Phase 3 Unknown
180 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Shengjing Hospital

Phase 3 Unknown
420 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡